Japan Tralokinumab Market

Japan Tralokinumab Market Summary:

According to Transpire Insight, a detailed research report on the Japan Tralokinumab Market reflects that Adtralza® (tralokinumab), marketed by LEO Pharma K.K., accounts for the primary product presence in Japan, with its 150 mg prefilled syringe priced at approximately JPY 29,295 per syringe and its 300 mg prefilled pen introduced in 2024, making LEO Pharma the key contributor to market development, innovation in IL-13-targeted biologic therapy, expanding treatment accessibility through home self-injection, and growth dynamics in Japan's atopic dermatitis treatment landscape. Japan-specific market revenue and percentage share figures are not publicly established.

Market Snapshot

• Market Value (2025): USD 43.6 Million.
• Expected Market Value (2026): USD 50.1 Million.
• Estimated Market Value (2033): USD 104.1 Million.
• Forecast CAGR (2026–2033): 11.01%.

Introduction

The Japan Tralokinumab Market represents the process of discovery, commercialization, marketing, and usage of tralokinumab, known as Adtralza, as a biologic treatment for moderate to severe atopic dermatitis in patients who are suitable candidates. Tralokinumab is a monoclonal antibody targeting interleukin-13 (IL-13), a cytokine which plays an important role in the development of inflammation and disease pathogenesis. Market dynamics are driven by the demand for innovative biologic products, changes in the approach to the treatment of dermatological disorders, and the requirement for long-term disease management in the case when standard therapy is ineffective. Infrastructure of the country’s healthcare system, availability of dermatologists in Japan, and the scheme of reimbursements will affect the treatment availability and uptake.

Key Market Highlights: -

• By Indication, the Adult Atopic Dermatitis dominated the market and holds approximately 53% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Patient Type, the Adults dominated the market and holds approximately 72% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Route, the subcutaneous injection Manufacturers segment dominated the market and holds approximately 80% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• The Japanese tralokinumab market will be influenced by rising demand for targeted biologics for atopic dermatitis, use of Adtralza, changing treatment approaches, and healthcare insurance coverage of eligible individuals.

How is Technology Driving Growth in the Japan Tralokinumab Market?

Technologies enable the Japan Tralokinumab Market mainly via innovations in biologics, drug delivery systems, and patient monitoring tools. Prefilled syringes and pen injection systems allow the subcutaneous administration of Adtralza to take place. Health technology applications and electronic medical records could be used by dermatologists to monitor medication compliance, severity of the condition, and patient-reported outcomes. Innovations in clinical data analysis could be used to make personalized decisions about the use of treatment, while the use of tralokinumab-specific AI-enabled dosing is currently not practiced. In addition, technologies in biopharmaceuticals production and logistics help ensure the quality and consistent distribution of medications.

Market Drivers

Japan Tralokinumab Market Growth can be attributed to the demand for a targeted biological therapy for patients with moderate-to-severe atopic dermatitis, along with the requirement for effective disease management. Adtralza is a biological drug developed by LEO Pharma, which blocks IL-13 selectively, thus providing another option for eligible patients, who have failed to respond to standard therapies. The presence of established dermatology care services and health insurance coverage in Japan help in gaining access to available biological drugs. Pre-filled syringe and pen-based delivery mechanisms increase the flexibility of administering the drug.

Restrain

The Japan Tralokinumab Market would be subjected to competition from existing biological therapies like dupilumab as well as JAK inhibitors taken orally. Affordability could be limited by high costs of therapy and pricing practices of the Japanese pharma industry. Furthermore, scientific research suggests heterogeneity in the effectiveness of therapy among patients, especially those who had previous experience with systemic therapy. Slow efficacy of the treatment might impact prescription and adherence rates.

Analysis of Prices and Consumer Behaviour

The Japan Tralokinumab Market is characterized by the use of biologic targeted therapy for moderate to severe cases of atopic dermatitis, which includes the biologic drug Adtralza (tralokinumab). No verified market share data and consumer purchase data is available for Japan, so the blueberry extract percentages cannot be directly transferred to this market due to the lack of reliable information. The cost of tralokinumab is determined by national pricing and reimbursement policies for drugs, and treatment usage is determined by clinical appropriateness and individual choice. Treatment demand is determined by a desire to maintain continuous control of the disease, treatment convenience, and access to biologics.

Who are the Key Players in the Japan Tralokinumab Market and how do they compete?

Japan Tralokinumab Market competitiveness requires companies with expertise in developing biologics, target drugs for atopic dermatitis, and pharmaceuticals logistics infrastructure. Competing not only through pricing but using advanced biologics, clinical differentiation, patient-centered solutions, and healthcare integration allows companies to develop their products further and make treatments more accessible, clinically effective, and patient-oriented.

Development of tralokinumab drug as a targeted inhibitor of IL-13 for atopic dermatitis allows LEO Pharma to strengthen its competitive position on the market. Development of Dupixent drug (dupilumab) as a targeted biologic for inflammatory diseases helps Sanofi differentiate itself among competitors. Development of its position through offering of Dupixent drug in collaboration with Sanofi company allows Regeneron Pharmaceuticals to help patients suffering from atopic dermatitis with biologic targeting.

Top Companies in the Japan Tralokinumab Market

1. LEO Pharma
2. Sanofi
3. Regeneron Pharmaceuticals
4. AstraZeneca
5. Eli Lilly
6. AbbVie
7. Pfizer
8. Novartis
9. Roche
10. GSK
11. Bristol Myers Squibb
12. Johnson & Johnson
13. UCB
14. Maruho
15. Torii Pharmaceutical

Japan Tralokinumab Market Segmentation

The Japan Tralokinumab Market share is divided into six categories: By Indication, By Patient Type, By Route, By Treatment Line, By Distribution Channel, By End User.

The Adult Atopic Dermatitis dominated the market, accounting for nearly 53% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan Tralokinumab Market is segmented by indicationinto atopic dermatitis, moderate-to-severe atopic dermatitis, severe atopic dermatitis, chronic eczema, other type-2 inflammatory conditions, pediatric atopic dermatitis, adult atopic dermatitis, adolescent atopic dermatitis. Among these, the Adult Atopic Dermatitis segment dominated the market, accounting for nearly 53% in 2025 and expected to increase at a significant CAGR during the forecast period. The adult atopic dermatitis segment was driven by a large patient base, significant disease burden, and increasing demand for efficacious treatment options.

The Adults dominated the market, accounting for nearly 72% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The Japan Tralokinumab Market is segmented by patient type into adults, adolescents, children, elderly, moderate cases, severe cases, refractory cases, long-term patients. Among these, the Adults dominated the market, accounting for nearly 72% in 2025 and expected to increase at a significant CAGR during the forecast period. The adults segment was dominant owing to the higher prevalence of atopic dermatitis and increased need for treatment among patients suitable for biologic drugs.

The subcutaneous injection dominated the market, accounting for nearly 80% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan Tralokinumab Market is segmentedby route into subcutaneous injection, prefilled syringe, autoinjector, clinic administration, home administration, loading dose, maintenance dose, other delivery forms. Among these, the subcutaneous injection dominated the market, accounting for nearly 80% in 2025 and expected to increase at a significant CAGR during the forecast period. The subcutaneous injection mode of administration dominated owing to the convenience and continuous drug delivery associated with subcutaneous injections.

Future Market Trends for the Japan Tralokinumab Market: -

1. Usage of Targeted Biologic Therapy: Japan has a market for tralokinumab that is driven by the demand for targeted treatments for eligible adults who have atopic dermatitis and cannot be treated through regular treatments.
2. Easy Administration: The Adtralza 300 mg auto-injector pen and eligibility for self-injection at home make the treatment easy to administer.
3. Clinical Studies and Availability of Drug: Clinical trials conducted in Japan proved tralokinumab to be an eligible treatment option.

Recent Development

• In January 2026: LEO Pharma provided evidence regarding the long-term effectiveness of tralokinumab for treating moderate to severe atopic dermatitis among Japanese patients based on real-world data post-Japan launch.
• In December 23, 2022: The MHLW of Japan granted an initial approval for Adtralza (tralokinumab) injection for subcutaneous use, thereby entering the regulatory market for atopic dermatitis treatment in Japan.
• In September 26, 2023: LEO Pharma released the first syringe formulation of Adtralza in Japan, increasing the availability of biological treatment for targeting IL-13 among adults with moderate to severe atopic dermatitis.
• In December 2, 2024: LEO Pharma released the 300 mg auto-injector pen formulation of Adtralza in Japan, providing a self-injection option for adult patients with atopic dermat

Market Segmentation

This study forecasts revenue at Japan, regional and country levels from 2020 to 2033. Transpire Insight has segmented the Japan Tralokinumab Market based on the below-mentioned segments:

Japan Tralokinumab Market, By Indication

• Atopic Dermatitis
• Moderate-to-Severe Atopic Dermatitis
• Severe Atopic Dermatitis
• Chronic Eczema
• Other Type-2 Inflammatory Conditions
• Pediatric Atopic Dermatitis
• Adult Atopic Dermatitis
• Adolescent Atopic Dermatitis

Japan Tralokinumab Market, By Patient Type

• Adults
• Adolescents
• Children
• Elderly
• Moderate Cases
• Severe Cases
• Refractory Cases
• Long-Term Patients

Japan Tralokinumab Market, By Route

• Subcutaneous Injection
• Prefilled Syringe
• Autoinjector
• Clinic Administration
• Home Administration
• Loading Dose
• Maintenance Dose
• Other Delivery Forms

Japan Tralokinumab Market, By Treatment Line

• First-Line Biologic
• Second-Line Biologic
• Post-Topical Therapy
• Post-Systemic Therapy
• Combination Therapy
• Monotherapy
• Maintenance Therapy
• Rescue Therapy

Japan Tralokinumab Market, By Distribution Channel

• Hospital Pharmacy
• Specialty Pharmacy
• Retail Pharmacy
• Specialty Distributors
• Direct Hospital Procurement
• Clinics
• Homecare Supply
• Other Channels

Japan Tralokinumab Market, By End User

• Hospitals
• Dermatology Clinics
• Allergy Clinics
• Specialty Centers
• Academic Medical Centers
• Research Institutes
• Pharmacies
• Home Healthcare